Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Douglas A. McIntyre | Feb 12, 2007 at 4:11 AM EST

Q3 is Key for Thermogenesis

Thermogenesis Corp (KOOL), a developer of cord blood collection and processing units, released subpar fiscal second quarter results on Friday.…

Douglas A. McIntyre | Feb 12, 2007 at 4:10 AM EST

Gilead Q4 Report: Preview of Great Things to Come

by JMHOBioTechnology Stock Blog Gilead (GILD) is a large biotech company with a portfolio of marketed products that include royalties…

Douglas A. McIntyre | Feb 10, 2007 at 12:08 PM EST

Friday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology REXAHN PHARMACEUTICL [RXHN.OB] +18.18% LPATH INC [LPTN.OB] +14.29% NEURALSTEM INC [NRLS.OB] +8.60% CELL GENESYS INC [CEGE]…

Douglas A. McIntyre | Feb 9, 2007 at 4:22 AM EST

Thursday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology AURIGA LABORATORIES [ARGA.OB] +22.32% ACCENTIA BIOPHARMACE [ABPI] +12.09% XENOPORT [XNPT] +11.09% CADENCE PHARM. INC. [CADX] +10.07%…

Douglas A. McIntyre | Feb 8, 2007 at 3:28 AM EST

Wednesday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology DYAX CORP [DYAX] +9.51% FERMAVIR PHARMACEUTL [FMVR.OB] +8.57% ZIOPHARM ONCOLOGY IN [ZIOP] +7.30% ALNYLAM PHARMACEUT [ALNY]…

Douglas A. McIntyre | Feb 8, 2007 at 3:27 AM EST

Federal Funding Constraints Forces Elimination of Cancer Trials

by H.S. AyoubBioHealth Investor.com Due to federal budget constraints some 3000 patients could possibly be prevented from taking part in…

Douglas A. McIntyre | Feb 8, 2007 at 3:26 AM EST

Follow Along with Dr. Frost and Invest in Continucare

One strategy that I like to follow when looking at smaller capped stocks is to keep an eye on company…

Douglas A. McIntyre | Feb 7, 2007 at 6:52 PM EST

Cramer Interviewed Celgene’s CEO

Cramer interviewed the CEO (Robert Hugin) of Celgene (CELG-NASDAQ), one name he has been very positive on before. Cramer said…

Douglas A. McIntyre | Feb 7, 2007 at 11:16 AM EST

3SBio IPO: Chinese Biotech Success

3SBio Inc. (SSRX-NASDAQ) opened at a premium to its pricing out of the chute today. The company priced 7.7 million…

Douglas A. McIntyre | Feb 7, 2007 at 4:04 AM EST

Tuesday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology XOMA LTD [XOMA] +11.15% DYADIC INTERNATIONAL [DIL] +9.27% ADVENTRX PHARMACTL [ANX] +6.01% VION PHARM INC [VION]…

Douglas A. McIntyre | Feb 7, 2007 at 4:03 AM EST

Thermogenesis Responds to FDA Questions

by H.S. AyoubBioHealth Investor.com On Tuesday Thermogenesis Corp (KOOL) announced that it had submitted the necessary paperwork answering certain questions…

Douglas A. McIntyre | Feb 6, 2007 at 4:00 AM EST

Monday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology HEMOBIOTECH INC [HMBT.OB] +9.52% AFFYMAX, INC. [AFFY] +7.03% OSIRIS THERAPEUTICS [OSIR] +6.93% IDM PHARMA INC [IDMI]…

Douglas A. McIntyre | Feb 6, 2007 at 3:58 AM EST

Indonesia Stops Sharing Bird Flu Samples Pending Baxter Collaboration

by H.S. AyoubBioHealth Investor.com According to the Financial Times, last month the Indonesian government stopped sharing key samples of H5N1…

Douglas A. McIntyre | Feb 4, 2007 at 1:39 PM EST

Friday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology SEATTLE GENETICS I [SGEN] +11.38% IMMUNOGEN INC [IMGN] +8.86% IDM PHARMA INC [IDMI] +8.58% SUNESIS PHARMACEUTIC…

Douglas A. McIntyre | Feb 4, 2007 at 1:38 PM EST

Access Pharmaceuticals Gains 70% on BusinessWeek Article

by H.S. AyoubBioHealth Investor.com I first mentioned Access Pharmaceuticals (ACCP.OB) way back in October after the company’s shares doubled on…

1 … 381 382 383 384 385 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Q3 is Key for Thermogenesis

Gilead Q4 Report: Preview of Great Things to Come

Friday’s Top Biotech and Medical Stocks

Thursday’s Top Biotech and Medical Stocks

Wednesday’s Top Biotech and Medical Stocks

Federal Funding Constraints Forces Elimination of Cancer Trials

Follow Along with Dr. Frost and Invest in Continucare

Cramer Interviewed Celgene’s CEO

3SBio IPO: Chinese Biotech Success

Tuesday’s Top Biotech and Medical Stocks

Thermogenesis Responds to FDA Questions

Monday’s Top Biotech and Medical Stocks

Indonesia Stops Sharing Bird Flu Samples Pending Baxter Collaboration

Friday’s Top Biotech and Medical Stocks

Access Pharmaceuticals Gains 70% on BusinessWeek Article

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Health and Healthcare Articles

All Health and Healthcare Articles

Q3 is Key for Thermogenesis

Gilead Q4 Report: Preview of Great Things to Come

Friday’s Top Biotech and Medical Stocks

Thursday’s Top Biotech and Medical Stocks

Wednesday’s Top Biotech and Medical Stocks

Federal Funding Constraints Forces Elimination of Cancer Trials

Follow Along with Dr. Frost and Invest in Continucare

Cramer Interviewed Celgene’s CEO

3SBio IPO: Chinese Biotech Success

Tuesday’s Top Biotech and Medical Stocks

Thermogenesis Responds to FDA Questions

Monday’s Top Biotech and Medical Stocks

Indonesia Stops Sharing Bird Flu Samples Pending Baxter Collaboration

Friday’s Top Biotech and Medical Stocks

Access Pharmaceuticals Gains 70% on BusinessWeek Article

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s